Skip to search formSkip to main contentSkip to account menu

nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

APD125

Broader (2)

Phenylurea CompoundsPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The Involvement of 5-HT 2A Receptor in the Regulation of Sleep and Wakefulness, and the Potential Therapeutic Use of Selective 5-HT 2A Receptor Antagonists and Inverse Agonists for the Treatment of…
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These… 
2018
2018
Serotonin Receptor Inverse Agonists or Antagonists for Use in Reducing Amyloid-Beta Peptides and Accumulation
Several approaches that are directed against amyloid plaque deposition, or against the formation of amyloid precursor protein… 
Review
2017
Review
2017
A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations (P6.088)
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations… 
Review
2017
Review
2017
Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists Specifically Promote Slow Wave Sleep (Stage N3) in Man
Several drug classes are widely prescribed when difficulties with sleep induction or sleep maintenance occur, as is the case in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)